US LNG exports surge but will buyers in China turn up?
In a recent transaction, Stephen H. Barnes, the Chief Financial Officer of Accolade, Inc. (NASDAQ:ACCD), sold shares valued at $3,577. This sale, executed on March 4, 2025, involved 514 shares of common stock at a price of $6.96 per share. The transaction occurs as ACCD shows strong momentum, with the stock up 65% over the past six months and more than doubling year-to-date, according to InvestingPro data. The transaction was conducted to fulfill tax withholding obligations arising from the vesting and settlement of restricted stock units (RSUs), as per a "mandatory sell to cover" arrangement.
Earlier, on March 3, Barnes acquired 1,569 shares of Accolade’s common stock at no cost, as part of the vesting of RSUs. This acquisition did not involve any discretionary action by Barnes, who now holds a total of 303,245 shares following these transactions.
In other recent news, Accolade Inc . has announced its acquisition by Transcarent, a private healthcare company, in a deal valued at $621 million. Accolade shareholders are set to receive $7.03 per share, marking a substantial 110% premium over the company’s closing stock price prior to the announcement. The acquisition is expected to close in the second quarter of 2025, and upon completion, Accolade will become a privately held company. Following the announcement, Raymond (NSE:RYMD) James adjusted its rating on Accolade from Outperform to Market Perform, noting the deal’s valuation at a 1.1 times revenue multiple and a 16.5 times EBITDA multiple, based on fiscal year 2026 estimates. Truist Securities, however, maintained a Buy rating on Accolade, reiterating a price target of $7.50 and highlighting the synergistic benefits of the merger. Stifel also downgraded Accolade from Buy to Hold, aligning its price target with the acquisition offer price of $7.03. The merger is anticipated to enhance Transcarent’s mission by integrating Accolade’s healthcare platform and expertise in health advocacy, expert medical opinions, and primary care. Accolade has withdrawn its previous financial guidance for the fiscal year but plans to report its third-quarter financial results within the previously provided guidance range.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.